Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention
Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the
Johns Hopkins Hospital, or the Johns Hopkins Health System nor by JAMA Ophthalmology.
This online activity targets healthcare gaps correlated with early intervention in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) without center-involved macular edema, which can have a profound impact on vision-related quality of life.
- By addressing these gaps, you can assess whether your approach to nAMD, DME and DR management through utilization of clinical trial data, guideline-based treatment approaches and patient-specific factors – could be modified to help both strategize treatment design and close these gaps.
- Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that early vs delayed intervention can have on vision-related quality of life.
- You will also be immersed in dynamic animations utilizing virtual reality and whiteboard platforms to memorably highlight key points related to how visual acuity is affected by intervention at different disease stages or treatment delay, as well as the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on the pathophysiologic defects associated with nAMD, DME and DR.
This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, and managed care professionals who manage patients with nAMD, DME, and DR in the absence of center-involved DME.
After completing the CME activity, learners should be better able to:
- Evaluate clinical trial evidence on the optimization of monitoring, treatment dosing, and the association of early intervention on visual acuity outcomes in neovascular AMD (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) in the absence of center-involved DME
- Assess the impact of treatments for nAMD, DME, and DR in the absence of center-involved DME on patients’ patient-reported vision-related quality of life
- How to develop treatment plans for the management of nAMD, DME, and DR in the absence of center-involved DME that incorporate evidence from clinical trials, guideline recommendations, and patient-specific factors
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with nAMD, DME, and DR in the absence of center-involved DME.
Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Neil Bressler, MD receives grants to his institution for his research efforts from Bayer, Biogen, Novartis, Roche/Genentech, and Samsung Bioepis. He also serves as Chair of the National Eye Institute Data and Safety Monitoring Committee for Intramural Trials for the Emmes Company. He is also Editor in Chief of JAMA Ophthalmology.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse.
The reviewer has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the enduring activity; and
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com.
RELEASE DATE: February 19, 2021
EXPIRATION DATE: February 19, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.